| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 18.3 | 17.2 |
| Profit before tax | -7.4 | -13.4 |
| Net income | -7.4 | -13.4 |
| EPS (diluted, $ a share) | $-0.26 | $-0.49 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +6.7% |
|---|---|
| Operating margin | -50.2% |
10-Q filed with the SEC, NASDAQ: ARCT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Arcturus Therapeutics Holdings Inc.: key numbers
- Share price
- $8.31Close, Nov 16
- Market cap
- $240M
- Shares outstanding
- 28.82MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Arcturus Therapeutics Holdings Inc.
All →Arcturus Therapeutics Holdings Capital Raise of $50M
Arcturus Therapeutics entered into a securities purchase agreement with Meiji Seika Pharma for the sale of 2,466,395 shares of common stock at $20.27 per share, raising $50 million in gross proceeds. The investment was made at an 80% premium to the 30-day average closing price and is part of an expanded collaboration including a license agreement for ARCT-154 technology and a pandemic preparedness MOU in Japan.
- Value
- $50M
- Counterparty
- Meiji Seika Pharma Co., Ltd.
“The investment, together with the license agreement and the pandemic preparedness MOU, reflects Meiji’s confidence in our development capabilities and the potential of our technology platform.”
Joseph Payne, President and Chief Executive Officer of Arcturus Therapeutics
Arcturus Therapeutics Holdings Financial Results
Arcturus Therapeutics reported Q3 2026 financial results, ending the period with $281.3 million in cash and equivalents. The company highlighted pipeline progress, including the completion of the myNEO acquisition and plans to complete enrollment for its ARCT-032 Phase 2 cystic fibrosis study by year-end 2026.
- Term
- Q3 2026
“The third quarter marked a pivotal step forward for our liver therapeutics franchise, with encouraging ARCT-810 Phase 2 results and the introduction of LUNAR 2.0™, our next-generation mRNA delivery platform, which demonstrated a 38-fold improvement over the key lipid in ARCT-810 in non-human primates.”
Joseph Payne, President & CEO of Arcturus
Arcturus Therapeutics Holdings Clinical Trial Data
Arcturus Therapeutics released Phase 2 clinical data for ARCT-810, its mRNA-based therapeutic candidate for Ornithine Transcarbamylase (OTC) deficiency. The company also provided a strategic update on its broader mRNA delivery platform and technology pipeline.